Prognostic Significance of KAI-1 and Survivin Expressions in Ovarian Epithelial Carcinomas.
- Author:
Ju Han LEE
1
;
Suk Min LEE
;
Jong Sang CHOI
Author Information
1. Department of Pathology, College of Medicine, Korea University, Seoul, Korea. jongchoi@kumc.or.kr
- Publication Type:Original Article
- Keywords:
Ovary neoplasm;
Survivin;
KAI-1
- MeSH:
Adenocarcinoma;
Blotting, Western;
Disease-Free Survival;
Down-Regulation;
Humans;
Mucins;
Ovarian Neoplasms;
Survival Rate;
Up-Regulation
- From:Cancer Research and Treatment
2003;35(4):323-329
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to evaluate the expressions of KAI-1 and survivin, and to investigate their correlation with the clinical stage and survival rate of patients with ovarian carcinomas. MATERIALS AND METHODS: The expressions of survivin and KAI-1 were immunohistochemically determined in 54 serous and mucinous ovarian adenocarcinomas and borderline malignancy tumors. 10 of the 54 cases were also analyzed for the expressions of survivin and KAI-1 using western blot. RESULTS: The down-regulation of the expression of KAI-1 was observed by immunohistochemical staining (IHC) in 53.7% of the ovarian cancers, and a negative reaction in 50% by the western blot analysis. From the IHC, the survivin expression was positive and strongly positive in 51.9 and 18% of the ovarian cancers, respectively. From the western blot analysis, 10% of the ovarian cancer showed positive reactions. The down- regulation of the KAI-1 expression was significantly correlated with the clinical stage (p=0.001) and disease free survival rate (p<0.001), but not with the histological type. The expression of survivin was not correlated with the clinical stage or histological type. However, the patients with a negative survivin expression had a significantly longer disease survival rate than those with a strong positive expression. CONCLUSION: The down- and up-regulation of the KAI-1 and survivin, respectively, might be independent prognostic factors in human ovarian carcinomas.
